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Abstract: The diseases caused by protozoan parasite are responsible for considerable mortality and morbidity, affecting 
more than 500 million of people in the world. The epidemiological control of protozoan is unsatisfactory due to difficul-
ties of vector and reservoir control; while the progress in the development of vaccine tends to be slow and arduous. Cur-
rently, the chemotherapy remains essential component of both clinical management and disease control programmer in 
endemic areas. The drugs in use as anti-protozoan agents were discovered over 50 years and a number of factors limit 
their utility such as: high cost, poor compliance, drug resistance, low efficacy and poor safety. In the recent years, the 
searches about the development of new drugs against protozoa parasite have been increased. This special issue of The 
Open Medicinal Chemistry Journal will present some of developments in this field with the aim to shown the significant 
advances in the discovery of new anti-protozoan drugs 
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INTRODUCTION 
  Protozoa parasites are composed by a very diverse group 
of unicellular eukaryotic organism from Protista kingdom, 
which present nuclei and other structures similar to animals. 
The main infections in human are due to protozoan of Plas-
modium, Trypanosoma and Leishmania genus. Others agents 
with medical importance exist, such as intestinal protozoa, 
Toxoplasma gondii and Trichomonas vaginalis. The proto-
zoan have been characterized as a diverse polyphyletic group 
that present a wide range of epidemiology characteristics and 
clinic manifestation in different geographic zones, particu-
larly in tropics and subtropics from developing countries 
(Table 1) [1-4].  
  The diseases caused by protozoan parasite are responsi-
ble for considerable mortality and morbidity, affecting more 
than 500 million of people in the world (Table 2). The his-
tory of protozoa infections in humans teaches us that im-
proved nutrition, economic development and public health 
measures are probably the deciding factors in increasing dis-
eases in the tropics [4, 5].  
  The study of protozoa biology has attracted the attention 
not only because they are fascinating organism, but also due 
to the need of finding tools and developing strategies to de-
crease the remarkable social and economic burden they 
cause on human societies [6]. The control of protozoan dis-
ease requires a complex interplay of activities in the fields of 
public health, education political will and medical science. 
However, the epidemiological control of protozoan is unsat-
isfactory due to difficulties of vector and reservoir control;  
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while the progress in the development of vaccine tends to be 
slow and arduous. Currently, the chemotherapy remains es-
sential component of both clinical management and disease 
control programmer in endemic areas [4]. 
CURRENT DRUGS TO PROTOZOAN DISEASES 
  Since the decade of 1930 was discoveries the conven-
tional drugs against protozoa disease, which presents general 
characteristics such as: (a) the compounds are formed by a 
low number of elements that including carbon, oxygen and 
nitrogen; while other elements are only present in specific 
structures, per example the sulphur; (b) the inorganic com-
pounds are scare, although can be used the arsenic and anti-
monies; (c) the annular structure are very common and the 
benzene are present in a high percent of compounds or have 
nitrogen; (d) the methyl, hydroxyl and amine group are very 
frequently; while the sulphydryl radical is absent [7]. Current 
drugs in use as anti-protozoan agents were discovered over 
50 years. A number of factors limit the utility of existing 
drugs (Table 3) in resource-poor setting, such as high cost, 
poor compliance, drug resistance, low efficacy and poor 
safety [1, 2, 5].  
DRUG DEVELOPMENT TO PROTOZOAN DISEASES 
  There is still a great need for drug development against 
protozoan diseases. The past 20 years has seen a significant 
increase in our basic knowledge of protozoa parasite. The 
currently search to develop new drugs have been facilitated 
by advances in sciences, especially in the field of parasite 
genomics (identification of unique metabolic pathways and 
key enzyme of the protozoa), chemistry methodologies 
(high-performance liquid chromatography (HPLC), nuclear 
magnetic resonance (NMR) and mass spectrometry) and 
bioinformatics tools (quantitative structure-activity relation2    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Monzote and Siddiq 
Table 1.  General Features of Main Protozoan Parasitic Diseases that Affect the Human Health 
Disease  Some Representative Etio-
logical Agents 
Geographical Localization  Clinical Features 
Malaria  Plasmodium falciparum, 
P. vivax 
Over 100 countries in the 
tropic and subtropics 
Fever, shivering, cough, respiratory distress, 
pain in the joints, headache, watery diarrhea, vomiting, 
convulsions severe anemia  
 African trypanosomiasis  Trypanosoma brucei  36 countries in sub-Sahara 
Africa 
Initial haemolytic phase (fever, joint pains followed by 
neurological disorder, somnolence 
Chagas disease  Trypanosoma cruzi  From northem Mexico to 
South Argentina 
Acute phase (fever and splenomegaly) 
Chronic phase (irreversible damage to heart, esophagus 
and colon) 
Leishmaniasis  Leishmania donovani,   L. 
major, L. mexicana,  L. 
braziliensis 
Over 88 countries in tropic and 
subtropics 
Skin ulcers, mucocutaneous complications and visceral 
diseases (hepatosplenomegaly) 
Toxoplasmosis  Toxoplasma gondii  Worldwide  Blindness and mental retardation can result in congeni-
tally infected children. 
Immunosuppressed patients can present more severe 
symptoms: splenomegaly, polymyositis, dermatomyosi-
tis, chorioretinitis, myocarditis, pneumonitis, hepatitis, 
encephalitis, and multisystem organ failure. 
Trichomoniasis  Trichomonas vaginalis  Worldwide  Vaginal discharge, odor and edema or 
erythema. 
Intestinal protozoan  Giardia lamblia,  Enta-
moeba histolytica, 
Cryptosporidium parvum, 
Cyclospora cayetanensis  
Worldwide  Hematuria, anemia, impaired growth. Renal, hepatic and 
spleen failure 
  
Table 2.  Summary of Statistics for Damage Caused by Main Parasitic Diseases 
Disease  Population at Risk (x10
6)  Number of People Infected (x10
6) Number  of  Death  (x10
3) 
Malaria  ~ 2 000  ~ 300  ~1000-2000 
African trypanosomiasis  ~ 60  ~ 0.3-0.5  ~ 50 
Chagas disease  ~ 40  ~ 17  ~ 21 
Leishmaniasis  ~ 350  ~ 2  ~ 59 
Intestinal protozoans  > 1000  ~ 450  ~ 40-100 
 
Table 3.  Limitations of Currently Used Drugs for Main Protozoan Diseases 
Disease  Some Current Used Drugs  Limitations 
Chloroquine, 1945  Resistance  Malaria 
Artemisin, 1994  Compliance, cost, manufacture 
Suramin, 1920  Safety, not effective in late-stage diseases, injectable 
Pentamidine, 1939  Safety, resistance, not effective in late-stage diseases, injectable 
African trypanosomiasis 
Melarsoprol, 1949  Safety, resistance, injectable Anti-Protozoan Drugs  The Open Medicinal Chemistry Journal, 2011, Vol. 5    3 
Table 3. Contd…. 
Disease  Some Current Used Drugs  Limitations 
  Eflornithine, 1991  Cost, injectable, only effective against T. gambiense 
Nifurtimox, 1970  Safety, long treatment, compliance, activity limited to acute stage of disease  Chagas disease 
Benznidazole, 1974  Safety 
Pentamidine, 1939  Safety, resistance, injectable 
Antimonials, 1950  Safety, resistance, injectable 
Liposomal amphotericin B, 1990  Cost, injectable 
Leishmaniasis 
Miltefosine, 2002  Contraindicated in pregnancy 
Sulfonamides, 1932  Safety, only in combined therapy  Toxoplasmosis 
Pyrimethamine, 1951  Safety, Contraindicated in pregnancy 
Trichomoniasis Metronidazole,  1955  Resistance 
Metronidazole, 1955  Resistance  Intestinal protozoan 
Diloxanide, 1956  Resistance 
 
ship (QSAR) modeling techniques) [8-12]. In parallel, recent 
development have been increased thanks to dedicated aca-
demic, public initiatives, private-public partnerships, phar-
maceutical industry and the experience of public health care 
organizations that focus on various aspects of drug discovery 
for infectious diseases, including the injection of new funds 
into this research area [13, 14]. Different strategies have 
been defined to develop new anti-protozoan drugs in 
short/medium time (optimization of therapy with existing 
drugs, development of analogs of current drugs, combination 
therapy with conventional drugs and identification of agents 
to use against other indications) and in large time (search 
new targets and rational drug design and natural products) 
[15].  
  This special issue of The Open Medicinal Chemistry 
Journal will present some of developments in this field with 
the aim to shown the significant advances in the discovery of 
new anti-protozoan drugs 
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